Friday, 06 Dec 2019

Biologic/Novel Rx

Date Typesort ascending Title Save
30 Aug 2016 Social Dr Carol Langford Gr Rounds - ANCA levels do NOT correlate well with disease activity and should not be used to guide therapy
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
09 Nov 2018 Social Frankincense is derived from Boswellia plants. Boswellia serrata is an Ayurvedic purported to be anti-inflammatory; inhibits 5-lipoxygenase & possibly prostaglandins, Pilot studies in OA have shown significant pain relief and improved physical function https://t.co/OPxal73aIF
28 Dec 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6 pages of overview/comparisons; 5 biologic handouts https://t.co/D80f7I6Sr7
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
07 Nov 2017 Social RT @DrPetryna: #16L #acr17 no risk of DVTorPE w/Tofa from RTC trials analysis. IRs comparable to #corona data for Tofa&cDMARDs @RheumNow ht…
22 Feb 2016 Social FDA has launch a CME course on biosimilars - reviews law, terminology, FDA approach to biosimilars https://t.co/5VDCzuiGNF
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX https://t.co/7lFqrfL3fF
14 Dec 2016 Social IL-33 a biomarker for RTX response - if RA pts are RF+ or CCP+; w/ detectable serum IL-33 & High IgG levels. https://t.co/meig18rSEX
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar. https://t.co/EkikDMU1u8
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co…
02 Aug 2017 Social FDA Arthritis Advisory Panel votes against (12-2) approval of Sirukumab (IL6 inhib) for use in RA. FDA decision pending.
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS https://t.co/c1PW8aglhU
13 Jun 2018 Social RT @FerreiraRJO: Excellent talk from Tracy French about how nurses can promote shared decision making with patients being proposed to switc…
14 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Still's disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
06 Jun 2016 Social Did you know that many (not all) biologics have latex? Dr. Dao writes how to Handle Latex Allergies w/ Biologics https://t.co/ToK3AmcAoX
22 Jul 2016 Social In Tofacitinib RCTs 1821 child-bearing age F exposed; 47 pregnant (33 monoRx). 1 Pulm valve stenosis, 7 Spont Abs. https://t.co/O2GT1BKiMT
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij